ASLAN Pharmaceuticals (NASDAQ: ASLN) Starts ASLAN004 Atopic Dermatitis Study
Hasnain R
September 24, 2020
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) has commenced the multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis